Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Study Identifier:
ALXN1840-WD-204
ClinicalTrials.gov Identifier:
NCT04573309
EudraCT Identifier:
2020-001104-41
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Available Documents

ProtocolStatistical Analysis Plan

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1840
Date
Sep 2020 - Jun 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1840
Date
Sep 2020 - Jun 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).

Trial Locations

Location
Status
Location
Research Site
New Haven, Connecticut, United States, 06510
Status
N/A
Location
Research Site
Grafton, New Zealand, 1010
Status
N/A
Location
Research Site
London, United Kingdom, SE1 1YR
Status
N/A